Evidence map›Paper›PMID 31919759›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer.

A Iglesias-Santamaría

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 13 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 13 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

A Iglesias-SantamaríaOncology Pharmacy Department, Hospital Universitario Lucus Augusti, Ulises Romero nº1, 27003, Lugo, Spain. araceli.iglesias.santamaria@sergas.es.ORCID http://orcid.org/0000-0003-4749-6069
Hospital Universitario Lucus Augusti · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRecent evidences support a role of gut microbiota in influencing the efficacy of immune checkpoint inhibitors (ICI). The use of antibiotics (ATB) and other concomitant medications may impair the balance of microbiota and negatively affect the efficacy of immunotherapy.

methodsRetrospective data analysis was performed on advanced cancer patients treated with ICI. Those receiving ATB within 4 weeks before or after initiating ICI were compared with those who did not. Likewise, those who received ATB (irrespective of time of onset) were compared with not exposed and was calculated the variable "ATB exposure" (AE) defined as the % "days of ATB/days of ICI". Use of proton pump inhibitors (PPIs), opioids and steroids was also evaluated.

resultsOf the 102 patients included, 60 (58.8%) received ATB during immunotherapy treatment (ATB+ group), and 33 (32.3%) received them between 4 weeks before or after starting ICI (ATB4+ group). Median AE of the ATB-treated patients was 11.1% (range 5.6-21.3). PFS and OS did not differ between ATB4+ and ATB4- group or between ATB+ group and not treated one. However, both PFS and OS were significantly lower in patients with a higher AE than the median one (3.1 vs. 8.2 months, p = 0.007; 9.4 vs. 17.8 months, p = 0.02, respectively). PPIs or steroids use did not affect clinical outcome of ICI but opioids use was significantly associated with lower PFS and OS (4.5 vs. 8.1 months, p = 0.010; 8.6 vs. 26.3 months, p < 0.001, respectively).

conclusionsCumulative ATB use, rather than simple use in a defined time frame, may impair the efficacy of immunotherapy. Opioids use was also associated with poorer outcomes in patients treated with ICI.

Indexed as

AgedAnti-Bacterial AgentsAntineoplastic Agents, ImmunologicalDrug InteractionsFemaleGastrointestinal MicrobiomeHumansImmune Checkpoint InhibitorsMaleMiddle AgedNeoplasmsNeoplasm StagingRetrospective StudiesSurvival RateAnti-Bacterial AgentsAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsAdvanced cancerAntibioticsDysbiosisGut microbiotaImmune checkpoints inhibitorsOpioids

Identifiers

PMID31919759
OpenAlexW3000170484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.